Company intelligence / Profile preview

NovaLead Pharma

Pune, Maharashtra, Indianovaleadpharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Galnobax® has successfully completed Phase I/IIa proof-of-concept global clinical trials and a recent Indian Phase III trial met both primary and secondary endpoints for wound closure in diabetic foot ulcer patients, demonstrating safety for long-term use. The company’s pipeline includes several additional candidates at preclinical or discovery stages targeting dermatological and metabolic diseases.

Therapeutic areas: OtherEndocrinologyDermatologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

NLP91

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed; business model focuses on outlicensing/partnering after first human proof of concept.

Beyond the preview

Go deeper on NovaLead Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaLead Pharma.

Explore the full profile